마이크로 RNA 시장 : 시장 예측(2026-2032년)

The microRNA Market is projected to grow by USD 21.85 billion at a CAGR of 29.88% by 2032.

MicroRNA Executive Summary: Precision Biology, Diagnostics, and RNA Therapeutics

MicroRNA (miRNA) has become a high-impact area of molecular biology, precision medicine, and translational research because these short non-coding RNA molecules regulate gene expression across development, immune response, metabolism, oncology, cardiovascular disease, neurological disorders, infectious disease, and rare disease pathways. The microRNA ecosystem spans discovery research, biomarker validation, diagnostic assay development, therapeutic target identification, oligonucleotide drug design, delivery technologies, sequencing workflows, PCR-based quantification, bioinformatics, and clinical-grade analytical validation. Scientific momentum is supported by public genomic resources, broader use of next-generation sequencing, single-cell and spatial biology platforms, and increasing recognition that circulating microRNAs in blood, plasma, serum, urine, saliva, and extracellular vesicles may support minimally invasive disease detection and patient monitoring. For industry stakeholders, the opportunity is defined not only by scientific novelty but also by the ability to convert microRNA biology into reproducible, regulated, clinically meaningful, and scalable applications. The field is advancing from exploratory expression profiling toward integrated multi-omics, companion diagnostics, RNA therapeutics, and AI-enabled biomarker discovery, while still requiring rigorous standardization in sample handling, normalization, assay reproducibility, patient stratification, and regulatory evidence generation.

Transformative Shifts in the MicroRNA Landscape

The microRNA landscape is undergoing transformative shifts as research moves beyond single-marker discovery toward network-level interpretation of gene regulation. Advances in RNA sequencing, digital PCR, microfluidics, extracellular vesicle isolation, and automated sample preparation are improving sensitivity and enabling microRNA detection from low-input and liquid biopsy samples. In diagnostics, microRNAs are increasingly evaluated as non-invasive biomarkers for cancer detection, treatment response monitoring, cardiovascular risk assessment, liver disease progression, neurodegenerative disease research, and inflammatory conditions. In therapeutics, the field is progressing through strategies that include microRNA mimics, antagomirs, locked nucleic acid-modified inhibitors, and targeted delivery systems designed to restore or suppress disease-associated microRNA activity. At the same time, the sector is shifting toward higher evidentiary standards, with emphasis on clinically annotated cohorts, cross-platform validation, quality-controlled biobanks, and harmonized reporting. Regulatory expectations for analytical validity, clinical validity, clinical utility, and manufacturing control are shaping product development pathways. The most important structural shift is the convergence of microRNA science with multi-omics, AI-based pattern recognition, and precision clinical trial design, creating a more integrated environment for biomarker-driven healthcare innovation.

Cumulative Impact of Artificial Intelligence on MicroRNA Innovation

Artificial intelligence is accelerating microRNA research by helping investigators identify expression signatures, predict microRNA-mRNA interactions, prioritize disease-relevant pathways, and integrate heterogeneous data from genomics, transcriptomics, proteomics, metabolomics, imaging, pathology, and electronic health records. Machine learning models are being applied to biomarker panel selection, disease classification, patient stratification, treatment-response prediction, and toxicity assessment. Natural language processing can support evidence mapping by extracting microRNA-disease associations from scientific literature and public databases, while graph-based models help characterize regulatory networks across complex biological systems. The cumulative impact of AI is particularly visible in oncology and liquid biopsy research, where high-dimensional datasets require advanced feature selection and robust validation to avoid overfitting. However, AI adoption in microRNA must be governed by transparent model development, representative datasets, bias assessment, explainability, external validation, and compliance with data protection regulations. The most durable gains will come from combining AI with standardized wet-lab workflows, high-quality clinical metadata, interoperable data formats, and prospective validation studies, ensuring that computational discoveries translate into reproducible diagnostic and therapeutic applications.

Key Regional Insights Across the Global MicroRNA Ecosystem

Asia-Pacific is a fast-evolving region for microRNA research, supported by expanding genomic medicine initiatives, strong academic output, growing biomanufacturing capabilities, and increasing adoption of sequencing and molecular diagnostics across China, Japan, South Korea, India, Australia, and ASEAN economies. Regional priorities include oncology, liver disease, infectious disease, cardiometabolic disorders, aging-related conditions, and population-scale genomics, supported by national precision medicine strategies and expanding clinical sequencing infrastructure. North America remains a central hub for microRNA translational science due to mature clinical research infrastructure, advanced regulatory pathways for molecular diagnostics and RNA-based therapeutics, extensive biobank networks, and strong investment in oncology, rare disease, and precision medicine programs. Latin America is building microRNA capability through university-led genomics research, oncology diagnostics modernization, infectious disease surveillance expertise, and expanding access to molecular testing in Brazil and Mexico, although infrastructure and reimbursement variability continue to influence adoption. Europe contributes through coordinated biomedical research programs, strong regulatory oversight for in vitro diagnostics, clinical biobanking standards, and active work in cancer, cardiovascular, metabolic, and neurological microRNA applications. The Middle East is increasing its focus on genomics, population health, and precision medicine, with microRNA research benefiting from national health transformation agendas, cancer center development, and investment in advanced diagnostics. Africa is emerging through genomics capacity building, infectious disease research networks, cancer research collaborations, and public health initiatives, with microRNA applications most likely to progress where sequencing infrastructure, biospecimen governance, ethical data stewardship, and international research partnerships are strengthened.

Key Group Insights Shaping MicroRNA Research and Adoption

ASEAN is gaining relevance in microRNA research through expanding biomedical science programs, regional cancer research collaborations, infectious disease expertise, and gradual adoption of advanced molecular diagnostics in countries with stronger laboratory infrastructure. The GCC is positioning precision medicine as part of health system modernization, with microRNA opportunities linked to oncology, inherited disease, cardiometabolic disorders, and national genomics initiatives. The European Union plays a major role in shaping microRNA development through harmonized clinical research standards, data protection rules, in vitro diagnostic regulation, cross-border research funding, and strong emphasis on reproducibility and patient safety. BRICS countries collectively bring scale, population diversity, scientific productivity, and growing biotechnology capabilities, making them important for microRNA biomarker discovery, validation in diverse cohorts, and cost-sensitive diagnostic innovation. G7 countries continue to lead in regulatory science, high-throughput platforms, translational medicine, clinical trial infrastructure, and standards-based evidence generation, supporting movement from microRNA discovery to clinically validated tools. NATO member countries, many of which overlap with advanced biomedical economies, contribute through resilient research infrastructure, biosecurity awareness, health technology collaboration, and investments in advanced diagnostics relevant to public health preparedness and precision medicine.

Key Country Insights for MicroRNA Development and Commercialization

The United States is a leading environment for microRNA innovation, supported by advanced academic medical centers, large-scale genomics programs, regulatory experience in molecular diagnostics, and extensive clinical trial activity in oncology and rare diseases. Canada contributes through strong public research systems, precision health initiatives, and expertise in bioinformatics and population-based studies. Mexico is expanding molecular medicine capabilities, particularly in cancer, metabolic disease, and infectious disease research, while continuing to address infrastructure and access gaps. Brazil has a significant research base in genomics, oncology, immunology, and infectious disease, making it central to Latin American microRNA development. The United Kingdom supports microRNA progress through genomic medicine infrastructure, biobanking, clinical data integration, and translational research networks. Germany is notable for engineering strength, molecular diagnostics, RNA biology research, and high-quality clinical laboratories, while France contributes through national biomedical research programs, oncology networks, and regulatory-aligned clinical studies. Russia has scientific activity in molecular biology and oncology-related microRNA research, although international collaboration conditions can affect momentum. Italy and Spain both contribute through cancer research institutes, cardiovascular research, neurobiology programs, and biobank-supported translational studies. China is rapidly advancing microRNA science through extensive sequencing capacity, large patient cohorts, RNA research, and precision medicine programs. India is strengthening its role through genomics, affordable diagnostics development, cancer biology, and infectious disease expertise. Japan combines deep RNA biology knowledge, advanced diagnostics, aging-related disease research, and strong clinical laboratory standards. Australia contributes through precision oncology, population genomics, and translational research networks, while South Korea is highly active in molecular diagnostics, biotechnology, sequencing, and oncology-focused biomarker research.

Actionable Recommendations for MicroRNA Industry Leaders

Industry leaders should prioritize clinically validated microRNA applications where biological relevance, unmet clinical need, and feasible regulatory pathways intersect. Diagnostic developers need to invest in standardized pre-analytical workflows, including biospecimen collection, storage, RNA extraction, hemolysis control, normalization strategy, and platform reproducibility. Therapeutic developers should focus on delivery, tissue targeting, immunogenicity mitigation, pharmacokinetics, off-target assessment, and durable manufacturing controls for oligonucleotide-based candidates. Organizations should build evidence strategies around multi-center cohorts, longitudinal sampling, diverse population representation, and independent external validation. Partnerships with hospitals, biobanks, sequencing laboratories, regulatory experts, and bioinformatics teams can reduce translational risk. AI teams should implement transparent model governance, version-controlled datasets, explainable algorithms, bias monitoring, and prospective validation. Commercial teams should avoid overreliance on exploratory signatures and instead emphasize clinical utility, workflow integration, reimbursement evidence, physician adoption, and patient-centered outcomes. Leaders that align microRNA discovery with regulatory-grade analytics, high-quality metadata, real-world evidence, and scalable assay formats will be better positioned to convert scientific findings into practical precision medicine solutions.

Research Methodology for Evidence-Based MicroRNA Intelligence

A robust microRNA research methodology should combine secondary evidence review, expert validation, and structured data triangulation. Secondary research should include peer-reviewed literature, clinical trial registries, regulatory guidance, patent publications, public genomic and transcriptomic databases, disease-specific biomarker repositories, and standards from recognized clinical laboratory and molecular diagnostics bodies. Primary validation should involve discussions with molecular biologists, clinical laboratory directors, pathologists, oncologists, cardiologists, neurologists, bioinformaticians, regulatory specialists, and translational research leaders. Analytical assessment should examine sample type, extraction method, detection platform, sensitivity, specificity, reproducibility, normalization controls, cohort design, and statistical robustness. For AI-enabled microRNA research, methodology should include dataset provenance, cohort diversity, feature selection controls, training and validation separation, model explainability, and independent replication. Regional and country-level analysis should consider research infrastructure, regulatory frameworks, clinical trial capacity, reimbursement environment, biobank quality, sequencing adoption, and precision medicine policy. This evidence-led approach supports objective interpretation without relying on market sizing, speculative forecasts, or unsupported commercial claims.

Conclusion: MicroRNA as a Strategic Driver of Precision Medicine

MicroRNA is advancing from a research-intensive field into a strategic pillar of precision diagnostics, biomarker discovery, and RNA-based therapeutic innovation. Its value lies in the ability to reveal disease-associated gene regulation patterns, support minimally invasive testing, and open new approaches to modulating biological pathways. Progress is strongest where scientific discovery is paired with standardized laboratory methods, clinically meaningful cohorts, AI-enabled analytics, regulatory discipline, and scalable translational infrastructure. Regional momentum across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa reflects a broadening global commitment to molecular medicine, although adoption will depend on evidence quality, affordability, laboratory capacity, and clinical workflow integration. For industry leaders, the path forward is clear: prioritize reproducibility, clinical utility, ethical data use, and cross-disciplinary collaboration. Organizations that build rigorous microRNA programs around validated biology, high-quality data, and patient-centered outcomes will be best positioned to shape the next generation of precision healthcare.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. microRNA Market, by Product & Services

• 7.1. Introduction
• 7.2. Instruments
  • 7.2.1. PCR Systems
  • 7.2.2. Microarray Platforms
  • 7.2.3. Next-Generation Sequencing (NGS) Systems
• 7.3. Consumables
  • 7.3.1. Kits & Reagents
  • 7.3.2. Probes & Primers
  • 7.3.3. Microarray Chips
• 7.4. Services

8. microRNA Market, by Technology

• 8.1. Introduction
• 8.2. Real-Time Polymerase Chain Reaction (RT-PCR)
• 8.3. Microarray
• 8.4. Next-Generation Sequencing (NGS)
• 8.5. Immunoassay
• 8.6. Nanoparticle-based Delivery Platforms

9. microRNA Market, by Application

• 9.1. Introduction
• 9.2. Cancer
  • 9.2.1. Lung Cancer
  • 9.2.2. Breast Cancer
  • 9.2.3. Colorectal Cancer
  • 9.2.4. Prostate Cancer
• 9.3. Cardiovascular Diseases
• 9.4. Neurological Disorders
• 9.5. Infectious Diseases

10. microRNA Market, by End-User

• 10.1. Introduction
• 10.2. Biotechnology & Pharmaceutical Companies
• 10.3. Academic & Government Research Institutes
• 10.4. Contract Research Organizations (CROs)
• 10.5. Clinical Laboratories
• 10.6. Hospitals & Diagnostic Centers

11. microRNA Market, by Region

• 11.1. Asia-Pacific
• 11.2. North America
• 11.3. Latin America
• 11.4. Europe
• 11.5. Middle East
• 11.6. Africa

12. microRNA Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. microRNA Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Share Analysis, 2025
• 14.2. FPNV Positioning Matrix, 2025
• 14.3. Market Concentration Analysis, 2025
  • 14.3.1. Concentration Ratio (CR)
  • 14.3.2. Herfindahl Hirschman Index (HHI)
• 14.4. Recent Developments & Impact Analysis, 2025
• 14.5. Product Portfolio Analysis, 2025
• 14.6. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. Abcam plc
• 15.2. Agilent Technologies, Inc.
• 15.3. Alnylam Pharmaceuticals, Inc.
• 15.4. Bio-Rad Laboratories, Inc.
• 15.5. BioGenex Laboratories, Inc.
• 15.6. Creative Biolabs Inc.
• 15.7. DiamiR Biosciences Corp.
• 15.8. Eurofins Scientific SE
• 15.9. F. Hoffmann-La Roche Ltd
• 15.10. GeneCopoeia, Inc.
• 15.11. GenScript Biotech Corporation
• 15.12. Horizon Discovery Group plc
• 15.13. Illumina, Inc.
• 15.14. InteRNA Technologies B.V.
• 15.15. LGC Limited
• 15.16. Merck KGaA
• 15.17. Miltenyi Biotec B.V. & Co. KG
• 15.18. MiNA Therapeutics Limited
• 15.19. miRecule, Inc.
• 15.20. NanoString Technologies, Inc.
• 15.21. New England Biolabs, Inc.
• 15.22. Novartis AG
• 15.23. PerkinElmer, Inc.
• 15.24. Promega Corporation
• 15.25. QIAGEN N.V.
• 15.26. Rosetta Genomics Ltd.
• 15.27. Sanofi SA
• 15.28. System Biosciences LLC
• 15.29. Takara Bio Inc.
• 15.30. Thermo Fisher Scientific Inc.